TCRCure

Executive Summary

TCRCure is a Chinese biotechnology company focused on developing innovative T-cell receptor (TCR)-based therapies for cancer and infectious diseases. Founded in 2016 and based in Suzhou, the company engineers T cells to recognize intracellular targets presented by HLA molecules, enabling treatment of solid tumors and virus-associated malignancies. TCRCure is advancing both autologous and allogeneic TCR-T cell therapies, with its pipeline currently in Phase 1 clinical development. The company's approach addresses the significant unmet need in targeting intracellular antigens, which has broader applicability than traditional chimeric antigen receptor (CAR) T-cell therapies. As a privately held company with 50-200 employees, TCRCure is positioning itself in the competitive TCR therapy landscape, leveraging China's robust biotech ecosystem. The company's early-stage status and focus on innovative TCR technology highlight its potential to contribute to next-generation cell therapies, though clinical validation remains pending.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data readout for lead TCR-T candidate in solid tumors40% success
• Q4 2026Partnership or licensing agreement for allogeneic TCR-T platform30% success
• Q1 2027Regulatory clearance for IND of second-generation TCR-T therapy50% success